Next Article in Journal
HEXIM1, a New Player in the p53 Pathway
Next Article in Special Issue
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy
Previous Article in Journal
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Open AccessReview

Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications

University College London, 5 University Street, London, WC1E 6JF, UK
Navarrabiomed Fundacion Miguel Servet, 3 Irunlarrea St., Hospital Complex of Navarra, 31008 Pamplona, Navarra, Spain
Author to whom correspondence should be addressed.
Cancers 2013, 5(3), 815-837;
Received: 10 May 2013 / Revised: 7 June 2013 / Accepted: 21 June 2013 / Published: 2 July 2013
(This article belongs to the Special Issue Cancers Gene Therapy)
The success of immunotherapy against infectious diseases has shown us the powerful potential that such a treatment offers, and substantial work has been done to apply this strategy in the fight against cancer. Cancer is however a fiercer opponent than pathogen-caused diseases due to natural tolerance towards tumour associated antigens and tumour-induced immunosuppression. Recent gene therapy clinical trials with viral vectors have shown clinical efficacy in the correction of genetic diseases, HIV and cancer. The first successful gene therapy clinical trials were carried out with onco(g-)retroviral vectors but oncogenesis by insertional mutagenesis appeared as a serious complication. Lentiviral vectors have emerged as a potentially safer strategy, and recently the first clinical trial of patients with advanced leukemia using lentiviral vectors has proven successful. Additionally, therapeutic lentivectors have shown clinical efficacy for the treatment of HIV, X-linked adrenoleukodystrophy, and b-thalassaemia. This review aims at describing lentivectors and how they can be utilized to boost anti-tumour immune responses by manipulating the effector immune cells. View Full-Text
Keywords: lentiviral vector; cancer immunotherapy; gene therapy; antigen presentation; dendritic cells lentiviral vector; cancer immunotherapy; gene therapy; antigen presentation; dendritic cells
Show Figures

Figure 1

MDPI and ACS Style

Liechtenstein, T.; Perez-Janices, N.; Escors, D. Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications. Cancers 2013, 5, 815-837.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop